---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111931"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:53:03.462038+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q3 net loss $102.2M; Type A FDA meeting positive for apitegromab BLA resubmission in 2026

## Summary
- Net loss $102.2M (EPS -$0.90) vs $64.5M (EPS -$0.66) YoY; no revenue.
- Cash $369.6M; plus ~$60M from warrants expiring Dec 31, 2025, expected to fund into 2027.
- Type A meeting with FDA completed Nov 12; BLA resubmission and U.S. launch for apitegromab in SMA anticipated in 2026.
- Second U.S. fill-finish facility secured; commercial capacity reserved starting Q1 2026.
- FDA cleared IND for SRK-439; dosing in healthy volunteers to begin Q4 2025.

## SEC filing metadata
- accession: 0001104659-25-111931
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/0001104659-25-111931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111931
- JSON: https://secwatch.observer/filing/0001104659-25-111931.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.